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Objective: Overexpression of Angiopoietin-like protein 2 (Angptl2) in obese adipose tissues promotes adipose tissue
inflammation and its-related metabolic abnormalities. In a comparative study with adiponectin, we investigated whether
alterations in serum Angptl2 concentrations reflect the effect of lifestyle intervention on weight loss and improved metabolic
parameters in overweight subjects.
Methods: A total of 154 Japanese men (age, 40.9±5.1 years; body mass index, 26.9±3.6kgm
 2; abdominal circumference,
94.1±8.9cm) underwent a 3-month lifestyle intervention and underwent follow-up for 3 months thereafter.
Results: Decreased serum Angptl2 levels, but not increased serum adiponectin levels, were immediately apparent at the end of
3-month lifestyle intervention. Angptl2 levels continued to decrease for 3 months in parallel with body weight loss and
improvement in metabolic indicators. In subjects showing X6% weight reduction, markedly reduced Angptl2 levels were
detected at the end of 3-month intervention, whereas increased adiponectin levels were detected 3 months after the end of
intervention. Multivariate analysis revealed changes in serum Angptl2 levels associated with changes in triglycerides (TGs),
aspartate aminotransferase and alanine aminotransferase. In contrast, changes in serum adiponectin levels were associated
with altered high-density lipoprotein cholesterol (HDL-C) and fasting plasma glucose levels.
Conclusion: A 3-month lifestyle intervention promoted weight reduction and improved glucose and lipid metabolism, an effect
maintained 3 months later. Notably, our findings indicate that decreased Angptl2 levels are a good indicator of reduced visceral
fat and metabolic improvement at early stages of lifestyle intervention. Thus, Angptl2 reflects adiposity and might
be a key protein to regulate inflammation and TG metabolism, whereas adiponectin levels could reflect improved glucose
and HDL-C metabolism.
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Introduction
Obesity is a pandemic medical and social problem that
increases lifestyle-related diseases, such as cardiovascular
disease, type 2 diabetes, hypertension, dyslipidemia
and cancer, all of which result in increased mortality.
1–5
Therefore, antagonizing weight gain is critical to decrease
occurrence of these diseases. Recent reports demonstrate that
weight loss has ameliorating effects on type 2 diabetes,
hypertension or dyslipidemia, independent of differences
in race, sex, age, intervention method and intervention
period.
6–9
Recently, the concept has emerged that obesity-related
inflammation is associated with high risk of type 2 diabetes
and cardiovascular diseases.
10–15 Circulating levels of
C-reactive protein (CRP), fibrinogen and some adipose
tissue-derived cytokines, all associated with inflammation,
are decreased by body weight reduction, an occurrence
associated with improved insulin resistance.
6,16–19
More recently, we revealed that circulating levels of
angiopoietin-like protein 2 (Angptl2), which is a stress
responsive adipose tissues-secreted protein, were higher than Received 2 September 2011; accepted 21 September 2011
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www.nature.com/nutdnormal in cases of obesity in human and mice, particularly
in cases with visceral fat accumulation, leading to chronic
adipose tissue inflammation and subsequent development
or progression of insulin resistance and metabolic
syndrome.
20–22 We observed accumulation of fat in the liver
and skeletal muscle was mild in Angptl2 knockout mice
compared with wild-type mice, and Angptl2 deletion
ameliorated adipose tissue inflammation.
20 We also observed
significant decreases in circulating Angptl2 concentrations
in obese diabetic men following treatment with the PPARg
agonist pioglitazone, and the percent decrease in Angptl2
levels was positively correlated with the percent decreases in
visceral fat area. These findings suggest that visceral fat is a
likely primary source of circulating Angptl2 and that levels of
that factor are significantly correlated with systemic insulin
resistance and inflammation.
20–22
But it remains unknown whether Angptl2 could respond
to weight reduction and its-related metabolic abnormalities
by lifestyle intervention, and if so, we’d like to know the
difference between angptl2 and adiponectin.
Thus, the aim of the present study was to investigate
whether Angptl2 levels reflect weight reduction, the degree
of weight reduction and obesity-related metabolic abnormal-
ities. For comparison, we monitored the influence
of weight reduction on adiponectin levels, which reportedly
increase in the circulation with weight loss and serve
as a biomarker to assess the improvement of obesity and
its-related metabolic abnormalities.
6–9
Materials and methods
Subjects
‘Overweight subjects’ were recruited to participate in a
lifestyle intervention program through newspaper or website
advertising. We defined the subjects with a body mass index
(BMI) X25.0kgm
–2 or an abdominal circumference X85cm
as ‘overweight subject’ in this study, because this criteria is
established as an adequate risk for categorizing ‘obesity
disease’ in Japan in relation to obesity-related complications
in Japan.
23 All subjects gave written consent after having
received verbal and written information about this
study. The Ethical Review Board of the Aichi Health Plaza
Comprehensive Health Science Center approved the study
procedures.
Study design
Subjects underwent lifestyle intervention for 3 months and
then were observed without intervention for 3 months
thereafter. At the beginning of intervention, and at the
3- and 6-month time points, a questionnaire about lifestyle,
anthropometric measurements, blood pressure (BP) measure-
ments and blood tests were performed. The questionnaire
contains smoking status, drinking habit and exercise
habit. For anthropometric measurements, height, weight,
abdominal circumference and body fat percentage (% fat)
were measured. For blood tests, triglyceride (TG),
high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), fasting plasma glucose
(FPG), hemoglobin A1c (HbA1c), serum insulin (insulin),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), high-sensitive CRP (hs-CRP), Angptl2 and adiponectin
levels were measured.
Lifestyle intervention
Subjects received detailed results of an examination that
they underwent at the beginning of intervention
and attended a lecture regarding the association of obesity
and health problems and the benefits of weight reduction.
That lecture included illustrations and graphs depicting the
relationship of lifestyle on metabolic syndrome-related
conditions. Subjects were then advised by support staff
(including a public health nurse, nutritionist and health
exercise trainer) to set their own behavioral targets. Then, for
3 months, subjects received lifestyle improvement support
for the purpose of weight reduction. Actually, subjects were
instructed in proper meal preparation for the energy-balance
or received support in the form of exercise training.
We instructed them by interview or supported them by
e-mail once or twice a month, depending on subjects’ living
conditions.
Anthropometric measurements
Weight was measured with the subjects wearing light
clothing and barefoot. BMI was calculated as weight (kg)
divided by height (m
–2). Body fat percentage was determined
using the bioelectrical impedance analysis (BIA) method
(TBF-102; Tanita Corporation, Tokyo, Japan). Abdominal
circumference was measured at the level of the umbilicus
(horizontal to the ground). Systolic and diastolic blood
pressure was measured using an automatic sphygmo-
manometer (SunTech Medical, Morrisville, NC, USA).
Biochemical analysis
Blood samples were taken after overnight fasting around at
0900 hours. LDL-C was measured using the direct method
(Determiner L, LDL-C, Kyowa Medex Co., Ltd, Tokyo, Japan).
HbA1c ( Japan Diabetes Society) was measured using the
latex agglutination method with a commercial test kit
(Kyowa Medex Co., Ltd, Tokyo, Japan). The HbA1c defined
by the National Glycohemoglobin Standardization Program,
which is the internationally used HbA1c, is expressed by
adding 0.4% to the HbA1c (JDS).
24 The HbA1c data are
shown by HbA1c (National Glycohemoglobin Standardiza-
tion Program). Insulin was measured using an enzyme
immunoassay with a commercial test kit (Eiken Chemical
Co, Ltd, Tokyo, Japan). Homeostasis model assessment of the
insulin resistance index (HOMA-IR) was calculated using a
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25 There is a good correlation
between HOMA-IR and glucose infusion rate obtained by the
euglycemic-hyperinsulinemic clamp method.
26 Given
the combination of accuracy and ease of testing, we use
HOMA-IR as an index of insulin resistance. Hs-CRP levels
were measured using the latex agglutination method with a
commercial test kit (N-assay LA, CRP-T, Nittobo, Tokyo,
Japan). Adiponectin was measured by ELISA using a test
kit (Adiponectin ELISA kit; Otsuka Pharmaceutical Co., Ltd,
Tokyo, Japan).
Angptl2 was measured by ELISA as previously
reported.
20,27 In brief, the K2-1A1 mouse monoclonal anti-
body was fixed to 96-well plates. After 10-fold dilution,
serum samples were immobilized on plates for 1h at 371C,
followed by washing with PBS containing 0.05% Tween20
(PBST) and addition of horseradish peroxidase-conjugated
K1-12A4 mouse monoclonal antibody. After 1h of incuba-
tion at 41C, plates were washed with PBS containing 0.05%
Tween20, and a tetramethylbenzidine detection reagent was
added to the wells. After 30min, the reaction was stopped by
addition of an equal amount of 1 N H2SO4, and absorbance
was measured at 450nm. We confirmed the validity of this
ELISA system through the following experiments. Absor-
bance at 450nm increased linearly with human Angptl2
calibrators of 50–350pg per assay with the least detectable
concentration of 50pg (correlation coefficient 40.99). In all
three intra-assay determinations of the same samples showed
coefficients of variation less than 5% at all Angptl2
concentrations tested. The mean±s.d. concentrations mea-
sured (and coefficient of variation) were: sample 1, 1.76±
0.05ngml
 1 (2.9%); sample 2, 0.43±0.01ngml
 1 (3.2%); and
sample 3, 0.14±0.01ngml
 1 (3.3%). The three inter-assay
determinations of the same serum gave coefficients of
variation of less than 10%: sample 1, 1.82±0.09ngml
 1
(5.2%); sample 2, 0.44±0.02ngml
 1 (4.6%); and sample 3,
0.142±0.01ngml
 1 (5.0%). Plasma concentrations of other
factors were determined using standard clinical bioche-
mistry methods.
Statistical analysis
To assess the effectiveness of lifestyle intervention, changes
in population characteristics at the beginning (0), end of the
3-month intervention or end of the 6-month program
(3-month intervention plus 3-month observation) were
assessed with the Wilcoxon signed rank test.
We used partial correlation analysis to examine association
between baseline Angptl2 or adiponectin levels and baseline
values of each laboratory measurement. We also analyzed
the association between changes in Angptl2 or adiponectin
levels and changes in each laboratory parameter, from the
beginning of the intervention to 3 and then 6 months later.
We tested baseline data and changes for normal distribution
by Kolmogorov–Smirnov method. From this result, we
logarithmically transformed TG, IRI, HOMA-IR, AST, ALT,
hs-CRP at baseline and changes in hs-CRP at 3 and 6 months.
Multiple linear regression analysis was conducted for each
change in BP, lipid metabolism, glucose metabolism and
liver function from the beginning of the intervention to
3 and 6 months, later as target variables, and values highly
correlated with each variation as explanatory variables.
Furthermore, subjects were grouped per 2% weight reduction
at 3 or 6 months after the beginning of intervention.
Changes in laboratory data values were analyzed by analysis
of variance or the Kruskal–Wallis test (for changes in diastolic
blood pressure and HbA1c after 3 months). Statistically
significant changes were compared using multiple compar-
ison by the Bonferroni method.
We used the statistics software PASW Statistics Base 18.0
(SPSS, Tokyo, Japan) and expressed results as means±s.d. or
s.e.m. Differences at the level of Po0.05 were considered
statistically significant.
Results
Baseline characteristics of subjects
A total of 154 men were enrolled. The average age was
40.9±5.1 years and BMI was 26.9±3.6kgm
–2 (Table 1).
Patients with an endocrine disorder or those undergoing
drug treatment for diabetes, hypertension or dyslipidemia
were excluded. Clinical and laboratory examination to
characterize baseline parameters before lifestyle intervention
revealed one patient with diabetes, which required therapy.
During the 3-month lifestyle intervention, seven subjects
dropped out of the study because of traffic accidents or
occupational reasons. During the subsequent 3-month
follow-up, 11 of the remaining 146 subjects could not be
followed for various reasons, such as occupational issues
or lack of motivation. Finally, 135 subjects who could be
followed for all 6 months of the program were analyzed
(continuation rate of 87.7%) (Figure 1).
At the baseline, correlation analysis adjusted by age
showed a significant positive correlation of Angptl2 levels
with adiposity, as estimated by BMI, abdominal circum-
ference and fat mass (Table 2a). In contrast, baseline
adiponectin levels showed an inverse correlation with
adiposity (Table 2a).
Correlation analysis adjusted by age and BMI to compare
baseline Angptl2 levels with clinical and laboratory data
showed a significant positive correlation of Angptl2 with
diastolic Blood Pressure, TG, Insulin and HOMA-IR and a
significant inverse correlation of Angptl2 with HDL-C
(Table 2b). By contrast, baseline adiponectin levels were
inversely correlated with TG, Insulin, HOMA-IR, AST, ALT
and hs-CRP, and showed a significant positive correlation
with HDL-C. Baseline Angptl2 and adiponectin levels showed
an inverse relationship trend (P¼0.056) (Table 2b). When we
added smoking status, drinking habit and exercise habit as
control variables, association between Angptl2 and adipo-
nectin at baseline was significant (r¼ 0.215, P¼0.014).
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after 3 and 6 months
As shown in Table 1, subjects’ weight at 3 and 6 months after
the beginning of lifestyle intervention was decreased
significantly compared with baseline values (reduced by
2.4±2. 5kg and 2.9±3.5kg, respectively). In addition,
BMI, abdominal circumference, % fat, fat mass, TG, LDL-C,
FPG, HbA1c, insulin, HOMA-IR, AST and ALT levels were
significantly reduced, indicating that the 3-month lifestyle
intervention significantly reduced adiposity and ameliorated
glucose and lipid metabolism. There was no significant
change in hs-CRP levels at 3 and 6 months after the
beginning of lifestyle intervention compared with those
observed at baseline. Serum Angptl2 levels were significantly
decreased from 3.02±1.18 to 2.79±1.11ngml
 1 (vs baseline
value, P¼0.001) 3 months after the beginning of interven-
tion, and significantly decreased to 2.65±1.08ngml
 1
(vs baseline value, Po0.001) at the 6-month time point.
Although serum adiponectin levels were expected to increase
based on previous reports,
6–9 they decreased from
6.59±3.78mgml
 1 to 6.22±3.94mgml
 1 (vs baseline value,
P¼0.001) by the 3-month time point. At the 6-month time
point, serum adiponectin levels were significantly increased
Table 1 Characteristics of the 135 subjects at 0 (baseline), 3 and 6 months after initiation of the intervention
Baseline 3 months P-value 6 months P-value
Age 40.9±5.1
Weight (kg) 79.4±11.8 77.0±11.5 o0.001 76.4±11.6 o0.001
BMI (kgm
 2) 26.9±3.6 26.1±3.6 o0.001 25.9±3.6 o0.001
Abdominal circumference (cm) 94.1±8.9 91.4±9.0 o0.001 90.5±9.5 o0.001
% fat (%) 26.6±5.4 24.6±4.7 o0.001 24.4±4.8 o0.001
Fat mass (kg) 21.6±7.5 19.4±6.7 o0.001 19.1±6.8 o0.001
SBP (mmHg) 121.6±12.4 121.9±11.9 0.523 121.7±12.3 0.992
DBP (mmHg) 72.4±10.3 76.6±9.9 o0.001 75.4±10.6 o0.001
TG (mg per 100ml) 149.8±114.2 122.6±71.7 o0.001 136.2±116.3 0.009
HDL-C (mg per 100ml) 58.4±13.2 55.5±12.1 o0.001 57.1±12.8 0.051
LDL-C (mg per 100ml) 134.8±35.3 125.1±31.0 o0.001 126.7±33.2 o0.001
LDL-C/HDL-C 2.43±0.84 2.39±0.86 0.166 2.35±0.89 0.155
FPG (mg per 100ml) 99.9±12.0 96.3±9.7 o0.001 96.3±9.9 o0.001
HbA1c (%) 5.38±0.45 5.20±0.36 o0.001 5.22±0.35 o0.001
Insulin (mcU ml-1) 10.12±9.17 7.37±5.14 o0.001 8.09±5.74 o0.001
HOMA-IR 2.57±2.71 1.79±1.37 o0.001 1.96±1.49 o0.001
AST (IUl
 1) 25.5±9.0 22.2±8.5 o0.001 23.0±8.7 0.005
ALT (IUl
 1 37.1±21.9 28.6±15.9 o0.001 30.0±20.2 o0.001
Hs-CRP (mg per 100ml) 0.086±0.156 0.086±0.125 0.907 0.090±0.120 0.811
Angptl2 (ngml
 1) 3.02±1.18 2.79±1.11 0.001 2.65±1.08 o0.001
Adiponectin (mcgml
 1) 6.59±3.78 6.22±3.94 o0.001 6.45±3.93 0.108
Abbreviations: Angptl2, angiopoietin-like protein 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of the insulin resistance index; Hs-CRP, high sensitive
C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride. Data are
presented as means±s.d. Statistical differences of clinical and laboratory data at the 3- and 6-month time points compared with baseline values were examined
using the Wilcoxon signed rank test.
Assessed for eligibility (n=154)
Did not meet inclusion criteria (n=1)
Began 3-month lifestyle intervention (n=153)
Withdrew (n=7)
due to occupation issues (n=6)
due to traffic accident (n=1)
Assessed for intervention effect
Began 3-month follow-up (n=146)
Withdrew(n=11)
due to occupation issues (n=8)
due to lack of motivation (n=2)
due to family illness (n=1)
Assessed for overall effect (n=135)
Figure 1 Flow of participants through the intervention and follow-up study.
Table 2a Correlations of Angptl2 and adiponectin levels with anthropo-
metric measurements at baseline levels
Angptl2 Adiponectin
rP r P
BMI 0.257 0.003  0.242 0.005
Abdominal circumference 0.262 0.002  0.321 o0.001
Fat mass 0.268 0.002  0.277 o0.001
Abbreviations: Angptl2, angiopoietin-like protein 2; BMI, body mass index.
Analysis was performed and adjusted by age. r and P indicate correlation
coefficients and P-values, respectively.
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however, they were not higher than baseline values
(vs baseline value, P¼0.108).
Changes in serum Angptl2 levels showed a significant
positive correlation with changes in BMI, abdominal
circumference and fat mass immediately after the interven-
tion, whereas those in serum adiponectin levels showed an
inverse correlation with BMI and fat mass values, but not
with abdominal circumference (Table 3). By the 6-month
time point, changes in serum Angptl2 levels continued to
show a significant positive correlation with BMI, abdominal
circumference and fat mass values, whereas serum adipo-
nectin levels were inversely correlated with these parameters
(Table 3).
Regarding changes in clinical parameters, decreases in
serum Angptl2 levels showed a significant positive correla-
tion with TG, AST, ALT and hs-CRP immediately after the
intervention, whereas those in serum adiponectin levels
showed a positive correlation with HDL-C and LDL-C. At the
end of the program, changes in serum Angptl2 levels showed
a significant positive correlation with TG, AST and hs-CRP
values, and an inverse correlation with HDL-C, whereas
serum adiponectin levels showed a positive correlation with
HDL-C values and an inverse correlation with FPG (Table 3).
Notably, we observed an inverse correlation between
Angptl2 and adiponectin levels after 6 months, but not after
3 months (r¼ 0.186, P¼0.032). Similar associations were
observed after 3 months and after 6 months when we added
smoking status, drinking habit and exercise habit as control
variables (r¼0.070, P¼0.432 and r¼ 0.203, P¼0.020,
respectively).
Table 2b Correlations of Angptl2 and adiponectin levels with blood pressure
and laboratory data at baseline levels
Angptl2 Adiponectin
rPrP
SBP 0.096 0.271  0.151 0.084
DBP 0.247 0.004  0.149 0.087
Log TG 0.255 0.003  0.291 0.001
HDL-C  0.424 o0.001 0.299 o0.001
LDL-C 0.070 0.421  0.112 0.200
FPG 0.085 0.331  0.069 0.432
HbA1c 0.039 0.657  0.108 0.217
Log Insulin 0.386 o0.001  0.235 0.006
Log HOMA-IR 0.368 o0.001  0.232 0.007
Log AST 0.100 0.250  0.193 0.026
Log ALT 0.058 0.506  0.240 0.005
Log Hs-CRP 0.093 0.287  0.278 0.001
Angptl2 FF  0.166 0.056
Adiponectin  0.166 0.056 FF
Abbreviations: Angptl2, angiopoietin-like protein 2; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure;
FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis
model assessment of the insulin resistance index; Hs-CRP, high sensitive
C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; SBP, systolic blood pressure;
TG, triglyceride. Analysis was performed and adjusted by age and BMI.
r and P indicate correlation coefficients and P-values, respectively.
Table 3 Correlations between changes in Angptl2 (left) and adiponectin (right) levels and changes in adiposity, blood pressure and laboratory data at 3 and
6 months after beginning the intervention relative to baseline data, which was estimated before the intervention began
From baseline DAngptl2 DAdiponectin
To 3 months To 6 months To 3 months To 6 months
rPrPr P rP
DAdiposity
DBMI 0.370 o0.001 0.362 o0.001  0.190 0.028  0.190 o0.001
DAbdominal circumference 0.265 0.002 0.311 o0.001  0.017 0.843  0.017 0.003
DFat mass 0.254 0.003 0.353 o0.001  0.209 0.015  0.209 o0.001
DClinical and laboratory data
DSBP 0.078 0.372 0.021 0.812 0.071 0.415  0.066 0.451
DDBP 0.165 0.057 0.119 0.172 0.106 0.226 0.044 0.612
DTG 0.360 o0.001 0.194 0.025 0.102 0.241 0.080 0.359
DHDL-C  0.055 0.526  0.196 0.024 0.203 0.019 0.369 o0.001
DLDL-C  0.114 0.193  0.100 0.250 0.179 0.039 0.145 0.096
DFPG 0.021 0.813 0.157 0.072  0.132 0.130  0.273 0.001
DHbA1c 0.082 0.350 0.107 0.221 0.134 0.123 0.045 0.610
DInsulin  0.086 0.324  0.037 0.676 0.040 0.649 0.081 0.355
DHOMA-IR  0.109 0.213  0.044 0.615 0.024 0.782 0.070 0.425
DAST 0.272 0.002 0.195 0.024 0.110 0.208  0.066 0.454
DALT 0.216 0.012 0.161 0.064 0.118 0.176  0.032 0.718
DLog Hs-CRP 0.241 0.005 0.257 0.003  0.062 0.480  0.021 0.809
DAngptl2 FFFF 0.068 0.436  0.186 0.032
DAdiponectin 0.068 0.436  0.186 0.032 FFF F
Abbreviations: Angptl2, angiopoietin-like protein 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of the insulin resistance index; Hs-CRP, high sensitive
C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride. Analysis
was performed and adjusted by age (for adiposity) and BMI (for clinical and laboratory data). r and P indicate correlation coefficients and P-values, respectively.
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examine which changes contributed to improvement of
clinical data. As shown in Table 4, changes in serum Angptl2
concentrations were positively correlated with diastolic
blood pressure, TG, AST and ALT values, whereas changes
in serum adiponectin concentrations were positively
correlated with HDL-C values at 3 months. At the end of
the program (6 months), changes in TG were positively
correlated with serum Angptl2 concentrations, whereas
changes in HDL-C were positively correlated with serum
adiponectin concentrations, while FPG changes were
inversely correlated with adiponectin levels.
Weight reduction rates and changes in laboratory parameters
At 3 and 6 months after the beginning of the intervention,
subjects were grouped by the degree of weight reduction rate
into 5 groups: a weight gain group (3 months; n¼19,
6 months; n¼23), the 0 to o2% weight reduction group,
which was designated as the unchanged control group for
the following analysis (3 months; n¼35, 6 months; n¼32),
the 2 to o4% weight reduction group (3 months; n¼41,
6 months; n¼26), the 4 to o6% weight reduction group
(3 months; n¼20, 6 months; n¼17 and the 6% or more
weight reduction group (3 months; n¼20, 6 months;
n¼37).
At the 3-month time point, one-way analysis revealed
significant differences in alteration in LDL-C, FPG, AST and
ALT among the 5 groups (Figure 2a). Multiple comparison
analysis revealed significant decreases in LDL-C in the 6% or
more weight reduction group and significant decreases in
ALT in the 4 to o6% weight reduction group compared
with the unchanged control group. At the 6-month time
point, one-way analysis revealed significant differences in
alteration of HDL-C, LDL-C, FPG, HbA1c, AST and ALT
among the 5 groups (Figure 2b). Multiple comparison
analysis showed significant decreases in LDL-C in the 6%
or more weight reduction group and decreases in AST and
ALT in the 4–o6% group and 6% or more compared with
the unchanged control group.
One-way analysis also revealed significant differences in
alteration of serum Angptl2 levels among the 5 groups at
both 3- and 6-month time points (Figures 2c and d), whereas
significant alterations in serum adiponectin concentration
were seen only at the 6 month time point. Serum Angptl2
concentrations tended to decrease with increased percentage
of weight reduction, and the 6% or more weight reduction
group showed a significant decrease relative to the
unchanged control group at both the 3- and 6-month time
points (Figures 2c and d). By contrast, serum adiponectin
concentrations tended to increase with increased percentage
of weight reduction, and the 6% or more weight reduction
group showed a significant increase compared with the
unchanged control group at 6 months after the beginning
of the intervention, a change that was not observed at the
3-month time point (Figures 2c and d).
Discussion
We conducted a 3-month lifestyle intervention for men who
were overweight and observed maintenance of weight
reduction for another 3 months thereafter. Significant
weight reduction was obtained, improved lipid and glucose
metabolism and lowered plasma liver enzymes were
observed immediately after the end of the 3-month lifestyle
intervention. Moreover, improvement was maintained until
the 6-month time point. Notably, decreased serum Angptl2
Table 4 Multiple linear regression analysis to examine changes in clinical data mediated by the intervention
Target variable Explanatory variable
DBMI DAbdominal Circumference DFat mass DLog Hs- CRP DAngptl2 DAdiponectin
b P b P b P b P b P b P
From baseline to 3months
DDBP 0.023 0.872 0.151 0.223  0.127 0.234  0.079 0.379 0.197 0.04 0.056 0.53
DTG  0.103 0.431 0.07 0.54 0.17 0.084  0.195 0.019 0.42 o0.001 0.077 0.348
DHDL-C  0.167 0.238 0.075 0.542 0.073 0.492  0.041 0.649  0.066 0.486 0.208 0.02
DLDL-C 0.531 o0.001  0.175 0.135 0.045 0.655 0.032 0.701  0.141 0.117 0.189 0.025
DAST 0.044 0.74 0.085 0.464 0.178 0.075  0.009 0.919 0.268 0.003 0.111 0.183
DALT 0.116 0.384  0.039 0.739 0.241 0.017  0.034 0.682 0.213 0.019 0.144 0.086
From baseline to 6months
DTG  0.079 0.642 0.168 0.272 0.088 0.455  0.015 0.868 0.221 0.023 0.129 0.177
DHDL-C  0.185 0.24 0.148 0.294  0.048 0.659  0.047 0.566  0.123 0.166 0.338 o0.001
DFPG 0.176 0.277  0.104 0.474 0.103 0.358 0.028 0.744 0.09 0.326  0.257 0.005
Abbreviations: Angptl2, angiopoietin-like protein 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of the insulin resistance index; Hs-CRP, high sensitive
C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride. Target
variables: changes in SBP, DBP, TG, HDL-C, LDL-C, FPG, HbA1c, insulin, HOMA-IR, AST and ALT levels from intervention onset to 3 and 6 months. Explanatory
variables: changes in BMI, abdominal circumference, fat mass, log hs-CRP, Angptl2 and adiponectin levels at 3- and 6-month time points.
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Nutrition and Diabeteslevels were seen immediately after the end of 3-month
lifestyle intervention and continued for the entire 6-month
period. This finding was significant in the 6% or more weight
reduction group. By contrast, an expected increase in serum
adiponectin levels was observed only in subjects with X6%
weight reduction at the 6-month time point.
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Figure 2 Changes in BP, laboratory parameters related to lipid and glucose metabolism and liver function, and serum Angptl2 and adiponectin levels in each
weight reduction group. (a, b) Changes are evaluated at 3 (a)a n d6( b) months after beginning the intervention. (c, d) Changes in serum Angptl2 and adiponectin
at 3 (c)a n d6( d) months after beginning the intervention. Vertical axes indicate changes in laboratory data, and the horizontal axes indicate percent weight
reduction. Data were analyzed by one-way analysis of variance analysis of variance and compared between groups by multiple comparisons using the Bonferroni
method. The Kruskal–Wallis test was used to evaluate changes in DBP and HbA1c at the 3-month point (a). Data are presented as means±s.e.m.
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Nutrition and DiabetesIn previously reported intervention studies, such as
the Diabetes Prevention Program,
28 the Finnish Diabetes
Prevention Study
29 and the Malmo feasibility study,
30 longer
6- or 12-month interventions supported on a one-to-one
basis by case managers were undertaken. By comparison, our
intervention was mild, because only one or a few case
workers were available to the subjects for 3 months.
However, it is noteworthy that our intervention resulted in
significant weight reduction and moreover, improvement
was maintained for another 3 months after the end of the
first 3-month intervention.
Many previous studies have shown that circulating
adiponectin concentrations are inversely correlated with
adiposity and BMI.
6–9 Decreased adiponectin was found in
cases of visceral fat accumulation, and, conversely, weight
reduction promoted adiponectin increases.
6–9 Here, signifi-
cantly increased serum adiponectin levels were not detected
until 6 months after the intervention was started, whereas
loss of body weight and adiposity as estimated by BMI,
abdominal circumference, percent fat and fat mass were
detected at 3 months after the beginning of intervention.
These facts might mean adiponectin responds to weight
reduction slowly, so early changes in labolatroy data might
not be induced by adiponectin.
Recently, the multimeric adiponectin is considered the
active form and is better correlated with metabolic para-
meters. Bobbert et al.
7 reported that weight reduction
brought increased quantities of high molecular weight
isoforms of adiponectin, but total adiponectin showed
no change. On the other hand, some studies have shown
increased total adiponectin by lifestyle intervention.
6,8
In this study, we measured total adiponectin, so further
studies will be needed for the multimeric adiponectin.
When we examined the association between weight
reduction percentage and adiponectin levels, adiponectin
began to increase in the 46% weight reduction group after
3 months and in the 44% weight reduction groups after
6 months; however, significant adiponectin increases
were restricted to the 46% weight reduction groups after
6 months. Thus, greater weight reduction over longer follow-
up periods are required to detect increases in circulating
adiponectin after an intervention is initiated. Nonetheless,
changes in HDL-C were positively correlated with serum
adiponectin concentrations, and changes in FPG and
adiposity as estimated by BMI, abdominal circumference
and fat mass showed an inverse relationship with adipo-
nectin levels. Overall, our observations suggest that adipo-
nectin might not be a highly sensitive marker of improved
metabolism at early time points when substantial weight loss
is not yet apparent, but rather may be a good marker of
metabolic improvement in the late phase based on normal-
ization of adipocytes following significant weight loss.
This idea is consistent with the idea that adiponectin is
produced from only adipocytes, and its production from
enlarged and/or inflammatory adipocytes seen in obesity is
significantly decreased.
6–9
Increased Angptl2 levels owing to visceral fat accumula-
tion cause chronic inflammation and subsequent metabolic
disturbance.
20–22 We found that Angptl2 levels tended to
decrease immediately in subjects showing 2% or more
weight reduction and continued until 3 months after the
intervention. Angptl2 gradually decreased with increased
( ( p=0.002 (p=0.001)
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Figure 2 Continued.
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Nutrition and Diabetesweight reduction, and those decreases in the 6% or more
weight reduction group were significant compared with the
unchanged control group, indicative of an early effect of
weight reduction on improved metabolism. We speculate
that differences in changes of circulating levels of Angptl2
and adiponectin after the intervention are due to the types
of cells expressing each factor: Angptl2 is produced by
adipocytes and other cell types, such as vascular endothelia
cells and monocyte/macrophages, while adiponectin
expression is restricted to adipocytes. Angptl2 level changes
showed a significant positive correlation with changes in
adiposity and levels of hs-CRP, TG, AST and ALT and a
significant inverse correlation with HDL-C and adiponectin
levels. By contrast, adiponectin levels showed a significant
positive correlation with changes in HDL-C and a significant
inverse correlation with the changes in FPG, adiposity and
Angptl2. Interestingly, Angptl2 and adiponectin levels
were inversely correlated. It is noteworthy that changes
in Angptl2 levels are closely associated with changes in
inflammation, TG metabolism and ALT, whereas changes in
adiponectin are associated with glucose metabolism.
There are several limitations to this study. We used BIA
method to determine body fat percentage. Some studies
showed a good relationship between BIA and dual-energy
X-ray absorptiometory,
31 whereas others indicate that the
BIA method lacked accuracy.
32 Further studies are required to
evaluate Angptl2 as an appropriate marker of amelioration of
obesity and its-related metabolic disturbances. In particular,
it is important to determine whether changes of Angptl2
observed here apply over longer follow-up periods and to a
wider population of subjects, such as females, or individuals
with severe obesity or with metabolic disease.
In conclusion, we showed that a 3-month lifestyle
intervention induced weight reduction and improved
glucose and lipid metabolism, changes that continued for
3 months thereafter. Our findings indicate that decreased
Angptl2 levels are a good indicator of reduced visceral fat
and metabolic improvement at early stages of lifestyle
intervention. Thus, Angptl2 reflects adiposity and might be
a key protein to regulate inflammation and TG metabolism,
whereas adiponectin levels could reflect improved glucose
and HDL-C metabolism.
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